Mirae Asset Global Investments Co. Ltd. Has $747,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mirae Asset Global Investments Co. Ltd. lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 112.7% in the third quarter, HoldingsChannel.com reports. The firm owned 6,002 shares of the biotechnology company’s stock after purchasing an additional 3,180 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $747,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC raised its holdings in Sarepta Therapeutics by 100.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 2,504 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Sarepta Therapeutics by 8.7% during the first quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock worth $679,000 after buying an additional 418 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after buying an additional 33,711 shares during the period. Central Pacific Bank Trust Division bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $414,000. Finally, Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares during the period. Institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Barclays cut their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 14th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, Citigroup decreased their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $123.29 on Friday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics, Inc. has a twelve month low of $75.69 and a twelve month high of $173.25. The stock has a market capitalization of $11.76 billion, a P/E ratio of 273.98 and a beta of 0.82. The company has a 50 day moving average of $127.42 and a 200-day moving average of $132.56.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the firm earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 1.48 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.